Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock dropped 3% after the clinical-stage biotechnology company announced it has commenced an underwritten public offering of shares of its common ...

The company’s application to the U.S. Office of the Comptroller of the Currency would, if approved, allow Circle to act as a ...